Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Alibaba Group (BABA) Q2 2025 Earnings: Key financials and quarterly highlights
Alibaba Group Holding Limited (NYSE: BABA) reported its second quarter 2025 earnings results today. Revenue was $33.7 billion, up 5% year-over-year. Net income attributable to ordinary shareholders grew 58% to
AMAT Earnings: Applied Materials Q4 revenue and profit increase YoY
Applied Materials, Inc. (NASDAQ: AMAT) announced financial results for the fourth quarter of 2024, reporting an increase in revenue and adjusted earnings. Adjusted earnings of the semiconductor technology company increased
What to expect when Target (TGT) reports its Q3 2024 earnings results
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday. The stock has gained 9% over the past three months. The retailer is scheduled to report its earnings results for
